Mode
Text Size
Log in / Sign up

NODI parameters ODI and V-ISO differentiate gliomas from brain metastases in contrast-enhancing regionsBrain scan technique helps tell gliomas from metastases

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that NODI parameters ODI and V-ISO can help differentiate gliomas from brain metastases in contrast-enhancing regions.

This meta-analysis evaluates the utility of Neurite orientation dispersion and density imaging (NODDI) parameters, specifically V-IC, V-ISO, and ODI, for differentiating gliomas from brain metastases (BMs). The analysis synthesized data from 10 studies to compare these metrics across different tumor types.

The results indicate significant differences in the contrast-enhancing regions. Specifically, the orientation dispersion index (ODI) was significantly lower in gliomas compared to BMs (effect size -1.43; 95% CI [-2.02, -0.85]). Additionally, the isotropic volume fraction (V-ISO) was significantly lower in gliomas than in BMs (effect size -0.98; 95% CI [-1.60, -0.37]). In a glioblastoma subgroup, V-ISO of the peritumoral edema area was also significantly lower in gliomas compared to BMs (effect size -0.73; 95% CI [-0.96, -0.50]).

The authors note that the study is limited by a small number of included studies. Despite these limitations, the findings suggest that NODDI parameters, particularly ODI and V-ISO, may be useful tools for clinical differentiation between gliomas and brain metastases. Clinical application should consider the current evidence base and the specific characteristics of the imaging cohort.

A new analysis of 10 studies suggests that a specialized MRI technique called neurite orientation dispersion and density imaging (NODDI) may help doctors tell the difference between gliomas and brain metastases. These two types of brain tumors can look similar on standard scans but require different treatments.

The analysis looked at three NODDI measurements: orientation dispersion index (ODI), intracellular volume fraction (V-IC), and isotropic volume fraction (V-ISO). The results showed that ODI and V-ISO were significantly lower in gliomas compared to brain metastases, especially in the contrast-enhancing region of the tumor. For glioblastomas, V-ISO in the surrounding edema area was also lower.

However, the study has important limitations. Only a small number of studies were included, and the analysis did not report on patient outcomes or safety. The findings suggest NODDI could be a useful tool, but more research is needed before it becomes standard practice.

For now, this imaging technique offers a promising way to non-invasively differentiate brain tumors, potentially reducing the need for biopsies. But patients should discuss all diagnostic options with their doctor.

What this means for you:
NODDI imaging may help distinguish gliomas from brain metastases, but more studies are needed.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: Differentiation between gliomas and brain metastases (BMs) remains a diagnostic challenge. Noninvasive imaging biomarkers could be advantageous in brain tumor discrimination. PURPOSE: We aimed to systematically review the studies that measured neurite orientation dispersion and density imaging (NODDI) parameters in patients with gliomas and BMs. DATA SOURCES: A literature search was conducted in 4 databases, including PubMed, Web of Science, EMBASE, and Scopus. STUDY SELECTION: Studies that measured NODDI parameters, such as intracellular volume fraction (V-IC), isotropic volume fraction (V-ISO), and orientation dispersion index (ODI) in both patients with glioma and patients with BM were included. DATA ANALYSIS: Quality was assessed using the modified Newcastle-Ottawa Scale checklist. Pooled standardized mean differences (SMDs) with corresponding 95% CIs were calculated using a random-effects model. Heterogeneity was evaluated using the statistic. Subgroup analysis was performed to explore sources of heterogeneity. Funnel plots, along with Begg and Egger tests were applied to investigate publication bias. DATA SYNTHESIS: Ten studies were ultimately included in the systematic review. We found significant SMDs for ODI (SMD = -1.43 [-2.02, -0.85]) and V-ISO (SMD = -0.98 [-1.60, -0.37]) between gliomas and BMs in the contrast-enhancing region. Also, for the glioblastoma subgroup, V-ISO of the peritumoral edema area showed a significant SMD (SMD = -0.73 [-0.96, -0.50]). No significant differences were found for other parameters. The heterogeneity turned from high to low in specific subgroups, including the glioblastoma subgroup. LIMITATIONS: Our meta-analysis is limited by small number of studies. CONCLUSIONS: NODDI parameters, particularly ODI and V-ISO, can be considered useful tools for differentiating gliomas from BMs. These findings highlight the potential of NODDI as a noninvasive imaging biomarker to improve the differential diagnosis of intracranial tumors.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.